insights_auto
Why is BT3 down ၅.၁၇%?
Dive Deeperchevron_right
BT3:FRA
Lineage Cell Therapeutics
၀.၇၉ €
arrow_downward
-၅.၁၇%(-၀.၀၄၃) 1D
အောက် ၁၄, GMT+၂ ၂၂:၀၀:၀၀ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BT3...
Open
၀.၇၉ €
High
၀.၇၉ €
Low
၀.၇၉ €
Mkt. cap
၂၃.၁၆ ကုဋေ
Avg. vol.
၃၇.၀၀
Volume
၀.၀၀
52-wk high
၁.၆၉ €
52-wk low
၀.၇၈ €
No. of employees
၇၅
Open
၀.၇၉ €
High
၀.၇၉ €
Low
၀.၇၉ €
Mkt. cap
၂၃.၁၆ ကုဋေ
Avg. vol.
၃၇.၀၀
Volume
၀.၀၀
52-wk high
၁.၆၉ €
52-wk low
၀.၇၈ €
No. of employees
၇၅
News stories
From web sources and news partners
Stocktwits
·
ပြီးခဲ့သည့် ၁ နာရီ
SKHY Tracks Worst Month Since Nasdaq Debut: SK Hynix Reportedly Wants To Ship More Chip Tools To China Before Building In US
Trefis
·
ပြီးခဲ့သည့် ၁၇ မိနစ်
The 52-Week-High List: 18 S&P 500 Names On Wednesday
Simply Wall Street
·
ပြီးခဲ့သည့် ၂၇ မိနစ်
What Alector Bears Saw Before The Fall
Investor's Business Daily
·
ပြီးခဲ့သည့် ၂ နာရီ
Tech Futures Fall; Anthropic Revenue Jumps, But Not Enough?
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics